Cutaneous melanoma

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune respo…

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…

This phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slo…

This early-phase trial is testing whether combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—can safely treat advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system fight cancer, while ibrutinib blocks enzymes that help canc…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This phase 2 trial is testing the drug ibrutinib in 18 people with stage IV melanoma that has not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The study aims to see if the drug can shrink tumors and how long it keeps t…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This study tested the drug nivolumab in 26 people with stage IIB or IIC melanoma that had been completely removed by surgery. The goal was to see if nivolumab, an immunotherapy that helps the immune system attack cancer cells, could prevent the melanoma from coming back. Particip…

This phase 3 trial compares a new drug, RPH-075, to the established immunotherapy Keytruda (both are forms of pembrolizumab) in people with advanced or spreading skin melanoma that cannot be surgically removed. The study aims to see if RPH-075 is as effective as Keytruda at shrin…

This study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…

This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar stays in the body and works as well as Keytruda in preventing the cancer fr…

This phase 2 pilot study tests whether adding the investigational drug vidutolimod to the immunotherapy nivolumab can destroy more melanoma tumors in lymph nodes or nearby skin areas before surgery. Participants have stage IIIB/C/D melanoma that has spread but not to distant orga…

This completed phase 2 trial tested whether adding alpha interferon to standard surgery helps prevent skin melanoma from returning. 278 participants with stage I-IV melanoma were assigned to one of six groups, including surgery alone, low or high dose interferon, chemotherapy, or…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This Phase 2 trial tested a combination of targeted drugs (vemurafenib and cobimetinib) and immunotherapy (atezolizumab and tiragolumab) given before surgery to 64 patients with high-risk stage III melanoma. The goal was to see if the treatment could eliminate or shrink the cance…

This phase 2 trial tested whether a reduced dose of chemotherapy drugs (fludarabine and cyclophosphamide) given before infusing a patient's own tumor-fighting immune cells (lifileucel) could work for advanced melanoma that has spread or can't be removed. Eleven adults with stage …

This study tested whether taking two targeted drugs (dabrafenib and trametinib) for 12 months after melanoma surgery could keep the cancer from returning. It included 870 adults with high-risk stage III melanoma that had a specific BRAF V600 mutation. Results showed the drug comb…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This early-phase study tested whether adding a TNF-blocking drug (infliximab or certolizumab) to standard immunotherapy (nivolumab and ipilimumab) is safe for people with advanced melanoma that has spread. The main goal was to find the best dose and check for serious side effects…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This early-phase study tested whether combining a topical cream (imiquimod) with an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced melanoma that has spread. Seven participants with stage IIIB to IV melanoma were enrolled. The goal was to see if …

This early-phase trial tested a combination of two oral drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to prior treatments. The main goals were to find a safe dose and see if the combination could shrink tumors. The study is compl…

This study tested a combination of two immunotherapy drugs, low-dose ipilimumab and pembrolizumab, in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors and improve survival. Participants receiv…

This phase 2 trial tested a combination of an experimental cancer vaccine (BNT111) and an immunotherapy drug (cemiplimab) in 184 adults with advanced melanoma that no longer responded to standard immunotherapy. Participants were randomly assigned to receive the combination or eit…

This phase II trial tested whether adding bevacizumab to the immunotherapy drug ipilimumab helps people with advanced melanoma that cannot be removed by surgery. The study enrolled 169 participants and measured overall survival and tumor progression. The goal was to see if the co…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This Phase 2 trial tested a modified polio virus called lerapolturev, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that had stopped responding to standard PD-1 therapy. The virus was injected directly into tumors to trigger an immune attack. R…

This trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons…

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to di…

This study tested Emotional Freedom Techniques (EFT), a therapy that combines talking with gentle tapping on acupressure points, in 56 people who had been treated for melanoma and were in remission. The goal was to see if EFT could reduce fear of the cancer coming back and improv…

This trial tests whether an online training course, called MelaMEd, can improve primary care doctors' ability to detect and manage melanoma, the most serious form of skin cancer. Participants—general practitioners, trainees, and pediatricians—answer questions and review skin lesi…

This study watched 152 melanoma patients who had their tumors surgically removed and then started nivolumab as part of their normal care. Researchers tracked how long patients stayed cancer-free, whether the cancer spread, and overall survival. The goal was to see how well the dr…

This completed study examined 127 melanoma patients to understand how the IL4I1 enzyme influences disease progression and resistance to treatments like immunotherapy and targeted therapy. Researchers analyzed blood and tumor tissue samples before and after treatment. The goal was…

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatmen…

This completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …

This completed study tested whether an interactive website could help 485 melanoma survivors do better at protecting their skin from the sun and checking their skin for new or returning cancers. Participants used the website and reported how often they used sunscreen, wore protec…

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E).…

This study looked at whether a special training program could help primary care doctors better spot and treat early-stage skin cancer, especially melanoma. Fifty-four doctors from two clinics took part. The training aimed to improve their knowledge and skills in identifying suspi…

This study looked at 73 people with many moles to see if certain mole features can help predict who is most likely to develop melanoma. Participants gave saliva samples and had their moles photographed and analyzed. The goal is to improve risk assessment and make melanoma screeni…

This completed study examined whether healthy skin near a melanoma tumor contains hidden cancer stem cells that might predict the disease's return. Researchers analyzed tissue from 226 people with early-stage melanoma to see if these cells are linked to 5-year survival. The goal …

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient charac…

This study looked at 631 advanced melanoma patients treated with immune checkpoint inhibitors. Researchers wanted to see if the time until a patient needs their next treatment or dies (TNT-D) is a good stand-in for overall survival. The goal was to find a quicker way to measure h…

This study tested a method to identify immune cells (T cells) that recognize unique mutations in tumors. Researchers took blood and lymph node samples from 25 patients with breast cancer or melanoma. The goal was to see if they could find and measure these cancer-specific immune …